Secondary Logo

Journal Logo

Clinical Science

HIV Infection Is Associated With Increased Risk for Acute Exacerbation of COPD

Lambert, Allison A. MD, MHS*; Kirk, Gregory D. MD, PhD†,‡; Astemborski, Jacquie MHS; Mehta, Shruti H. PhD, MPH; Wise, Robert A. MD*; Drummond, M. Bradley MD, MHS*

Author Information
JAIDS Journal of Acquired Immune Deficiency Syndromes: May 1, 2015 - Volume 69 - Issue 1 - p 68-74
doi: 10.1097/QAI.0000000000000552

Abstract

INTRODUCTION

Chronic obstructive pulmonary disease (COPD), a predominantly tobacco-related lung disease characterized by fixed airflow obstruction, recently became the third leading cause of death in the United States.1 Acute exacerbation of COPD (AECOPD) is distinguished by an acute worsening of the patient's respiratory symptoms that is beyond normal day-to-day variations, which leads to a change in medication (eg, corticosteroids, antibiotics).2 The health impact of AECOPD is considerable, with substantial associated morbidity, health care resource utilization, disease progression, and mortality.3–8 Among patients with COPD in the general population, factors, such as reduced lung function and prior AECOPD, are strongly predictive of subsequent AECOPD.2,9

HIV infection is a risk factor for myriad incident pulmonary diseases, in particular, COPD.10,11 Furthermore, poorly controlled HIV infection, as marked by high viral load or low CD4 count, is independently associated with more rapid lung function decline.12 However, HIV-infected individuals receiving highly active antiretroviral therapy (HAART) were less likely to be aware of their diagnosis than persons not in care, likely reflecting the severity of lung disease in persons on antiretroviral therapy.13 Given the increasing burden of COPD among aging HIV-infected patients, studies identifying risk factors for sequela of COPD are needed. To date, studies of AECOPD in the setting of HIV infection have not been reported. To address this gap, we sought to determine the risk factors for AECOPD in the AIDS Linked to the IntraVenous Experience (ALIVE) cohort, a population at-risk and with HIV and COPD.14 ALIVE is comprised of current or former injection drug users (IDUs) who undergo regular behavioral, clinical, and spirometric measurement. The prevalence of tobacco use,15 HIV, and obstructive lung disease13 within this cohort, along with thorough symptom and disease assessments, allow for the observation of incident AECOPD and the identification of sociodemographic, behavioral, and clinical risk factors for AECOPD. We hypothesized that specific clinical factors, including reduced forced expiratory volume in 1 second (FEV1) and HIV infection, would be associated with increased risk of AECOPD in this at-risk population.

METHODS

Study Population

Briefly, ALIVE is an ongoing prospective, community-based cohort that has followed persons with a history of injecting drugs in Baltimore, MD, since 1988. Participants are seen every 6 months for the collection of clinical, demographic, behavioral, and laboratory data. Prebronchodilator spirometry was added to routine data collection at all ALIVE study visits in 2007. A complete description of the ALIVE study has been previously reported.14,16,17 ALIVE study visits are conducted with trained personnel to enhance self-reported medical history and medications. Participant encounters with the health care system are identified and medical record review with systematic data abstraction is performed. For this study, COPD was defined using modified GOLD classification of FEV1/forced vital capacity <0.70.2,18 Participants in this analysis included 167 ALIVE participants who met COPD criteria at each spirometry measurement performed between January 2007 and December 2010. This selection criterion was used to exclude participants with asthma, which is characterized by variable airflow obstruction over time. This study was approved by the Institutional Review Board of Johns Hopkins University and was conducted in accordance with the Helsinki Declaration of 1975, as revised in 2000. All participants provided written informed consent.

Data Collection

Demographic and clinical characteristics were collected using standardized study questionnaires; comorbidities were gathered through self-report and standardized medical record review. Specifically, smoking patterns, IDU status, and antiretroviral use were gathered through self-report. Hepatitis C virus (HCV) serology testing was performed at the first study visit after 2006 (Ortho Diagnostics; Rochester, NY). HIV serology status was confirmed at each study visit (for HIV-uninfected persons); CD4 count and HIV RNA testing (Amplicor HIV-1 Monitor test version 1.5; Roche Molecular Systems, Pleasanton, CA) were performed at each study visit (for HIV positives).

Prebronchodilator spirometry measurements, calculations, and interpretation were conducted in accordance with the American Thoracic Society guidelines.19 COPD disease severity was defined by FEV1 criteria: FEV1 ≥80% predicted (mild disease), FEV1 50%–79% predicted (moderate disease), and FEV1 <50% predicted (severe disease).18 AECOPD, assessed at each 6-month study visit, was defined as answering “yes” to the question “In the last 6 months, have you had a worsening of your breathing status requiring treatment with antibiotics or steroids?” Participants who answered “yes” to the any of the following questions “Have you received treatment for (diabetes, hypertension, hyperlipidemia, heart disease, renal disease, seizures disorder, stroke, or cancer) in the last 6 months?” were defined as having “comorbid disease.”

Statistical Analyses

Descriptive characteristics of the study population are presented as frequencies, mean (SD) for normally distributed data, and median [interquartile range (IQR)] otherwise; comparisons were conducted using the t test, Wilcoxon rank-sum test, or Pearson χ2, as appropriate. A 2-sided P value ≤0.05 defined statistical significance. The outcome of interest was AECOPD as defined above. The 6-month study intervals were considered discrete units of analysis. Because participants contributed multiple visits to analysis, regression models with generalized estimating equations20 were used to allow repeated measurements within the same individual. We first identified factors associated with AECOPD in univariable analysis. These factors, along with those determined to be of clinical relevance (ie, age), had a P value <0.2, and were included in a multivariable model to determine independent association of each covariate. Self-reported sociodemographic and clinical measures (body mass index, HIV, and HCV serology) were obtained from the visit at which the outcome of interest was ascertained. In multivariable models, spirometric measurements were obtained from the study visit preceding the outcome of interest because AECOPD can acutely lower FEV1. Comorbid disease status was also obtained from the study visit preceding the outcome of interest to reduce the ascertainment bias associated with these 2 measures. HIV-related variables were modeled separately and included HIV serostatus, HIV RNA categories [undetectable (<50 copies/mL) and detectable (≥50 copies/mL)] and CD4 count categories (defined as ≥350 and <350 cells/mm3 based on exploratory data analysis and prior publications within this cohort).21 Separate multivariable models included a prior episode of AECOPD were generated. All analyses were performed using SAS version 9.0 (SAS Institute Inc., Cary, NC).

RESULTS

Participant Characteristics

At baseline, the 167 ALIVE participants included in this study had a mean age of 52 years; 89% were black, 30% were female, 85% were HCV seropositive, and 32% HIV infected (Table 1). The median CD4 count was 312 cells per cubic millimeter (IQR, 193–454) among those with HIV infection, with 72% reporting HAART use within the past 6 months and 54% having an undetectable viral load (≤50 copies/mL). Among those with detectable HIV RNA, the median viral load was 4859 copies per milliliter (IQR, 1184–34,350). The majority of participants were current smokers (90%) with a median of 24 pack-years smoked (IQR, 15–38). According to modified GOLD criteria, participants predominantly had mild (41%) or moderate airflow obstruction (47%). A total of 82 (49%) of the participants reported receiving treatment for a comorbid disease in the past 6 months. Among participants with HCV antibody seropositivity, 83% of had detectable HCV RNA with a median HCV RNA level of 6.26 log10 copies per milliliter (IQR, 5.87–6.70). Participants had a median of 3 visits (IQR, 2–5) during a median of 1.5 years of follow-up (IQR, 0.5–2.1). A total of 552 visits occurred during the study period with AECOPD occurring at 53 visits (9.6% of all person-visits). Of the 36 individual participants experiencing an exacerbation, 24 participants had 1 exacerbation, 9 had 2 exacerbations, 1 had 3 exacerbations, and 2 had 4 exacerbations.

T1-9
TABLE 1:
Sociodemographic, Behavioral, and Clinical Characteristics at Baseline

Univariable Associations With AECOPD

Univariable logistic regression analysis identified factors associated with increased odds of AECOPD (see Table S1, Supplemental Digital Content, https://links.lww.com/QAI/A636), including female gender, receiving treatment for another comorbid disease, severity of airflow obstruction, and HIV status. HIV infection was associated with increased odds of AECOPD [odds ratio (OR), 2.18; 95% confidence interval (CI): 1.07 to 4.44, P = 0.032] in univariable analysis. Age, body mass index, black race, smoking pack-years, and injection drug use status (current versus former) were not significantly associated with risk of AECOPD. Neither HCV antibody seropositivity nor HCV RNA levels were significantly associated with AECOPD risk.

Multivariable Associations With AECOPD

Multivariable logistic regression analysis incorporating significant variables identified from univariate analyses as well as clinically relevant factors were generated. HIV infection was modeled separately with HIV serostatus, viral load categories, and CD4 cell count categories. Several factors were consistently associated with increased odds of AECOPD across models, including female gender, treatment for comorbid disease, smoking pack-years, and worsening airflow obstruction severity (Table 2). After adjusting for these factors and age, HIV infection was independently associated with a 2.47-fold increased odds of AECOPD (95% CI: 1.22 to 5.00). In HIV viral load models with HIV uninfected as the referent group, HIV-infected participants with undetectable HIV RNA (<50 copies/mL) had increased odds of AECOPD (OR, 2.91; 95% CI: 1.26 to 6.71), whereas persons with detectable HIV RNA levels (≥50 copies/mL) were no longer significantly different from HIV-uninfected persons (OR, 1.82; 95% CI: 0.70 to 4.78). When modeling HIV infection based on CD4 count, participants with a CD4 count ≥350 cells per cubic millimeter had increased odds of AECOPD as compared with HIV uninfected (OR, 4.16; 95% CI: 1.87 to 9.27). HIV-infected participants with a CD4 count <350 cells per cubic millimeter did not demonstrate elevated odds of AECOPD as compared with HIV negatives (OR, 1.17; 95% CI: 0.41 to 3.31). Including HAART status in either the HIV RNA or CD4 multivariable models did not alter the primary findings. To account for potential ascertainment bias, we performed stratified analysis by whether persons had received treatment of other comorbid conditions or not. Irrespective of the marker examined (HIV status, HIV RNA level, CD4 count), the observed risk estimates for AECOPD were similar to those in the primary analysis albeit with less precision due to smaller strata (data not shown). Higher CD4 cell counts (>350 cells/mm3) were notably associated with higher AECOPD risk both in persons receiving treatment (adjusted OR, 4.36; 95% CI: 1.37 to 13.84) for a comorbid disease other than COPD and in person not on such treatment (adjusted OR, 4.72; 95% CI: 1.48 to 15.02).

T2-9
TABLE 2:
Multivariable Models of AECOPD

Role of Prior AECOPD

Because a history of AECOPD is a risk factor for future exacerbations,9 we evaluated the association between AECOPD in the visit immediately before the visit where the outcome was analyzed. Prior exacerbation was strongly associated with future exacerbation (OR, 4.46; 95% CI: 1.99 to 10.00) in univariate analysis. Inclusion of prior AECOPD into multivariable models demonstrated that prior AECOPD was independently associated with increased occurrence of AECOPD, after adjusting for age, gender, comorbid disease, smoking pack-years, and severity of airflow obstruction (OR, 3.76; 95% CI: 1.57 to 8.97; Table 3). Inclusion of prior AECOPD into our models attenuated the increased odds of AECOPD observed with HIV serostatus and undetectable viral load; however, HIV participants with CD4 count ≥350 cells per cubic millimeter remained at increased odds of AECOPD compared with HIV-uninfected participants (OR, 3.23; 95% CI: 1.29 to 8.12; P = 0.12; Table 3).

T3-9
TABLE 3:
Multivariable Models of AECOPD With Inclusion of Prior AECOPD

DISCUSSION

HIV infection has become increasingly recognized as a risk factor for the development of COPD,11,22–24 yet little is known about the association between HIV infection and AECOPD. In this study of 167 ALIVE participants with COPD, HIV infection was independently associated with increased odds of AECOPD, even after adjusting for other AECOPD risk factors. AECOPD has been variably defined in prior studies25; our method relying on self-report of change in respiratory symptoms requiring treatment has been widely applied in major COPD trials.26–28 AECOPD was most common in persons receiving treatment for other comorbid disease and among HIV-infected participants with well-controlled HIV disease as measured by CD4 count and viral load, indicating increased ascertainment of AECOPD among persons engaged in regular care for HIV and comorbidities. However, compared with HIV-uninfected persons, those persons with HIV and higher CD4 cell counts had a greater than 4-fold higher likelihood for AECOPD irrespective of whether they were engaged in care for comorbidities other than COPD or not. These data highlight the complicated relationship between HIV infection and AECOPD risk, and draw attention to the need for HIV care providers to consider AECOPD across the spectrum of HIV disease severity.

To the best of our knowledge, this is the first report to describe an independent association of HIV infection with AECOPD. Several biological mechanisms may contribute to the increased risk of AECOPD observed among those with HIV infection. First, HIV infection has long been known to increase the incidence of lower respiratory tract infections,29,30 and these lower respiratory tract infections in turn may provoke an AECOPD.31,32 Second, in addition to increasing risk of respiratory infections through impaired immune function, HIV also paradoxically causes chronic, though aberrant, immune activation.33,34 Third, the lymphocytic alveolitis35,36 implicated in COPD pathogenesis among HIV-infected persons may contribute to increased AECOPD risk. Finally, systemic inflammation and risk for AECOPD has been shown to exist within the general COPD population37 and could be enhanced among those with comorbid HIV and COPD. Persons living with HIV infection suffer increased age-associated non–AIDS-related morbidity and mortality thought to be due to persistent inflammation caused by viral replication, viral expression, and loss of immunoregulatory cells.38 Increased levels of inflammatory biomarkers have been shown to correlate with all-cause mortality39; however, the specificity of these biomarkers for respiratory disease incidence, morbidity, and mortality remains unclear.

In addition to biological mechanisms for higher AECOPD risk with HIV infection, our data also suggest an increased recognition and management of AECOPD in persons effectively engaged in HIV care with higher CD4 cell counts or with virological suppression. This finding is not surprising considering that our AECOPD definition requires appropriate recognition and management of worsening respiratory symptoms. Participants with controlled viremia and higher CD4 cell counts may be more likely to regularly see a physician for their HIV care and thereby also more likely to be diagnosed and treated appropriately for AECOPD, as compared with HIV-infected persons not engaged in care or to HIV-uninfected persons in our cohort with limited access to care.

However, our data also suggest that access to appropriate care is unlikely to fully account for all of the observed association between HIV and AECOPD. First, other risk factors for AECOPD identified in this cohort including severity of airflow obstruction and prior AECOPD history are strongly consistent with those from general population studies, providing some face validity.2,9 Second, using self-reported treatment of comorbidities other than COPD as a surrogate marker for having access to care, we analyzed whether HIV status, viral load, and CD4 count remained associated with AECOPD. Irrespective of comorbidity treatment, HIV infection and related markers were consistently associated with AECOPD to a similar degree as in the primary analysis. Notably, the increase in AECOPD risk observed among HIV-infected participants with higher CD4 counts was >4-fold higher than in those without HIV infection irrespective of comorbidity treatment. Based on limited clinical data from disparate populations, it has been hypothesized that manifestations of obstructive lung disease may more apparent with more intact immune function, such as in the setting of immune reconstitution with HAART. We have previously found that markers of more advanced HIV disease are associated with the severity of airflow obstruction and with declines in lung function over time,12,19 findings which differ from the relationship between intact immune status and AECOPD observed here. There are several potential explanations for these observations. From an analytical perspective, participants in this analysis included those with established COPD, compared with inclusion of all ALIVE participants (the majority without pre-existing lung disease). Levels of HIV immunosuppression may differentially impact those with and without established disease. In this article, we adjusted for current FEV1 in our models to isolate the HIV effect on AECOPD risk from the impact of severity of airflow obstruction, whereas prior analyses incorporated FEV1 as an outcome of interest. These differing findings may represent a reporting bias in the structure of this analysis. The definition of AECOPD in this analysis required access to health care to be diagnosed with AECOPD, and that access to health care is associated with improved markers of immune function. However, we attempted to account for this bias by incorporating a variable of comorbid disease as a marker of access to care. From a biological perspective, AECOPD is classically characterized as a robust inflammatory and immune-mediated response40 that may be more likely to occur among HIV-infected individuals with well-controlled disease with an intact immune system. This is in contrast to FEV1 decline over time, which may be mediated by chronic low-grade inflammation41 as is observed in HIV-infected individuals with poorly controlled disease.33,42 Furthermore, the importance of the level of CD4 cell counts in the lung mucosa may be more relevant than the CD4 count in the peripheral compartment.43–45 We have recently reported that persons with COPD and HIV exhibit profound CD4+ T-cell depletion with reduced CD4/CD8 T-cell ratios in the bronchoalveolar lavage as compared with the periphery and compared with those with COPD alone. Moreover, HIV infection results in an altered respiratory microbiome, which may contribute to the increased AECOPD risk.46–48 The findings presented here offer additional insight into the complicated relationship between HIV-related immunosuppression and different lung outcomes.

Within the general COPD population, severity of airflow obstruction and prior AECOPD history have been consistently reported as the most important risk factors for future AECOPD.37,49,50 Specifically, a history of frequent AECOPD (>2 per year)4,49 and lower FEV149,51 have been shown to increase risk for future AECOPD and hospitalization for AECOPD. Our findings were consistent with these data from the general population, with a dose–response relationship between AECOPD risk and severity of airflow obstruction as measured by FEV1. In our analysis, prior AECOPD was the strongest factor associated with current AECOPD risk, attenuating the FEV1, HIV serostatus, and viral load, but not CD4 count, associations in adjusted models. This observation is consistent with studies of the general COPD population9 and highlights that regardless of HIV control, providers should recognize the impact of past AECOPD events on the future COPD course. We hypothesize that HIV infection may increase risk for incident AECOPD, which leads to a pathway of repeated AECOPD.

Previously, we have shown a substantial burden of respiratory symptoms among both HIV-infected and uninfected persons with a history of injecting drugs.52 Despite these respiratory symptoms and a high prevalence of tobacco exposure, approximately half of participants with spirometry-defined obstructive lung disease were unaware of their diagnosis.19 These findings along with our observations linking engagement in care to appropriate diagnosis and management of AECOPD and of the impact of prior AECOPD upon risk for future AECOPD emphasize the critical need to consider the diagnosis of COPD and occurrence of AECOPD within at-risk HIV populations. Unrecognized COPD can lead to misclassification of AECOPD as acute respiratory infections, thereby missing an opportunity to appropriately treat an AECOPD.

This study has limitations. Our cohort includes urban dwelling, African American current, and former IDUs, which limits the generalizability of our results to other HIV-infected and at-risk populations. However, the IDU population with high smoking prevalence represents the group of individuals at greatest risk for COPD. We do not have postbronchodilator spirometry to ensure the presence of fixed airflow obstruction seen in COPD; however, we required participants to have airflow obstruction at every spirometric measurement thereby reducing the likelihood of persons having primarily reversible airflow obstruction (ie, asthma). Finally, we do not account for the treatment of COPD within our analysis, which may have reduced the risk for AECOPD and potentially impacted our results. Data regarding inhaled medications were not regularly collected in ALIVE, so we are unable to fully assess the impact of medications on AECOPD outcomes.

In conclusion, HIV was significantly associated with AECOPD, even after accounting for factors, such as comorbid disease, smoking pack-years, and severity of airflow obstruction. The increased risk of AECOPD observed among HIV-infected participants with intact CD4 counts and viral suppression may reflect the multiple ways HIV infection imparts on AECOPD risk. HIV care providers should consider a diagnosis of AECOPD in HIV-infected patients at-risk for COPD given the association between these 2 disease processes.

ACKNOWLEDGMENTS

The authors thank the ALIVE staff and participants.

REFERENCES

1. Centers for Disease Control and Prevention (CDC). Chronic obstructive pulmonary disease among adults–United States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61:938–943.
2. From the global strategy for the diagnosis, management and prevention of COPD, global initiative for chronic obstructive lung disease (GOLD) 2013. Available at: http://www.goldcopd.org/. Accessed October 21, 2013.
3. Wedzicha JA, Wilkinson T. Impact of chronic obstructive pulmonary disease exacerbations on patients and payers. Proc Am Thorac Soc. 2006;3:218–221.
4. Seemungal TA, Donaldson GC, Paul EA, et al.. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1418–1422.
5. Patil SP, Krishnan JA, Lechtzin N, et al.. In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med. 2003;163:1180–1186.
6. Donaldson GC, Seemungal TA, Bhowmik A, et al.. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847–852.
7. Celli BR, Thomas NE, Anderson JA, et al.. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178:332–338.
8. Spencer S, Calverley PM, Burge PS, et al.. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J. 2004;23:698–702.
9. Hurst JR, Vestbo J, Anzueto A, et al.. Susceptibility to exacerbation in chronic obstructive pulmonary disease. New Engl J Med. 2010;363:1128–1138.
10. Crothers K, Huang L, Goulet JL, et al.. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med. 2011;183:388–395.
11. Crothers K, Butt AA, Gibert CL, et al.. Increased COPD among HIV-positive compared to HIV-negative veterans. Chest. 2006;130:1326–1333.
12. Drummond MB, Merlo CA, Astemborski J, et al.. The effect of HIV infection on longitudinal lung function decline among IDUs: a prospective cohort. AIDS. 2013;27:1303–1311.
13. Drummond MB, Kirk GD, Astemborski J, et al.. Prevalence and risk factors for unrecognized obstructive lung disease among urban drug users. Int J Chron Obstruct Pulmon Dis. 2011;6:89–95.
14. Vlahov D, Anthony JC, Munoz A, et al.. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr. 1991;109:75–100.
15. Marshall MM, Kirk GD, Caporaso NE, et al.. Tobacco use and nicotine dependence among HIV-infected and uninfected injection drug users. Addict Behav. 2011;36:61–67.
16. Vlahov D, Graham N, Hoover D, et al.. Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. JAMA. 1998;279:35–40.
17. Salter ML, Lau B, Go VF, et al.. HIV infection, immune suppression, and uncontrolled viremia are associated with increased multimorbidity among aging injection drug users. Clin Infect Dis. 2011;53:1256–1264.
18. Mannino DM, Doherty DE, Sonia Buist A. Global initiative on obstructive lung disease (GOLD) classification of lung disease and mortality: findings from the atherosclerosis risk in communities (ARIC) study. Respir Med. 2006;100:115–122.
19. Drummond MB, Kirk GD, Astemborski J, et al.. Association between obstructive lung disease and markers of HIV infection in a high-risk cohort. Thorax. 2012;67:309–314.
20. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121–130.
21. Kirk GD, Astemborski J, Mehta SH, et al.. Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis. 2009;48:963–972.
22. Diaz PT, King MA, Pacht ER, et al.. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. Ann Intern Med. 2000;132:369–372.
23. Morris A, George MP, Crothers K, et al.. HIV and chronic obstructive pulmonary disease: is it worse and why? Proc Am Thorac Soc. 2011;8:320–325.
24. Petrache I, Diab K, Knox KS, et al.. HIV associated pulmonary emphysema: a review of the literature and inquiry into its mechanism. Thorax. 2008;63:463–469.
25. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl. 2003;41:46s–53s.
26. Vestbo J, Group TS. The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J. 2004;24:206–210.
27. Burge PS, Calverley PM, Jones PW, et al.. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320:1297–1303.
28. Vestbo J, Edwards LD, Scanlon PD, et al.. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365:1184–1192.
29. Wallace JM, Hansen NI, Lavange L, et al.. Respiratory disease trends in the pulmonary complications of HIV infection study cohort. Pulmonary complications of HIV infection study group. Am J Respir Crit Care Med. 1997;155:72–80.
30. Hirschtick RE, Glassroth J, Jordan MC, et al.. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. N Engl J Med. 1995;333:845–851.
31. White AJ, Gompertz S, Stockley RA. Chronic obstructive pulmonary disease. 6: the aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax. 2003;58:73–80.
32. Sethi S, Evans N, Grant BJ, et al.. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002;347:465–471.
33. Boasso A, Shearer GM. Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin Immunol. 2008;126:235–242.
34. Derdeyn CA, Silvestri G. Viral and host factors in the pathogenesis of HIV infection. Curr Opin Immunol. 2005;17:366–373.
35. Guillon JM, Autran B, Denis M, et al.. Human immunodeficiency virus-related lymphocytic alveolitis. Chest. 1988;94:1264–1270.
36. Twigg HL III, Spain BA, Soliman DM, et al.. Production of interferon-gamma by lung lymphocytes in HIV-infected individuals. Am J Physiol. 1999;276:L256–L262.
37. Groenewegen KH, Postma DS, Hop WC, et al.. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest. 2008;133:350–357.
38. Deeks SG. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med. 2009;17:118–123.
39. Kuller LH, Tracy R, Belloso W, et al.. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203.
40. Papi A, Luppi F, Franco F, et al.. Pathophysiology of exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3:245–251.
41. Donaldson GC, Seemungal TA, Patel IS, et al.. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005;128:1995–2004.
42. Desai S, Landay A. Early immune senescence in HIV disease. Curr HIV/AIDS Rep. 2010;7:4–10.
43. Lin RY, Lazarus TS. Asthma and related atopic disorders in outpatients attending an urban HIV clinic. Ann Allergy Asthma Immunol. 1995;74:510–515.
44. Gutin F, Butt A, Alame W, et al.. Asthma in immune-competent children with human immunodeficiency virus. Ann Allergy Asthma Immunol. 2009;102:438.
45. Popescu I, Drummond MB, Gama L, et al.. Activation-induced cell death drives profound lung CD4 T cell depletion in HIV-associated COPD. Am J Respir Crit Care Med. 2014;190(7):744–755.
46. Cui L, Morris A, Huang L, et al.. The microbiome and the lung. Ann Am Thorac Soc. 2014;11(suppl 4):S227–S232.
47. Lozupone C, Cota-Gomez A, Palmer BE, et al.. Widespread colonization of the lung by Tropheryma whipplei in HIV infection. Am J Respir Crit Care Med. 2013;187:1110–1117.
48. Ireland AW, Ghedin E, Pop M, et al.. Comparison of the respiratory microbiome in HIV-infected and HIV-uninfected individuals. Am J Respir Crit Care Med. 2012;185:A4045. Available at: http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2012.185.1_MeetingAbstracts.A4045.
49. Garcia-Aymerich J, Monso E, Marrades RM, et al.. Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation. EFRAM study. Am J Respir Crit Care Med. 2001;164:1002–1007.
50. Miravitlles M, Guerrero T, Mayordomo C, et al.. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration. 2000;67:495–501.
51. Marin JM, Carrizo SJ, Casanova C, et al.. Prediction of risk of COPD exacerbations by the BODE index. Respir Med. 2009;103:373–378.
52. Drummond MB, Kirk GD, Ricketts EP, et al.. Cross sectional analysis of respiratory symptoms in an injection drug user cohort: the impact of obstructive lung disease and HIV. BMC Pulm Med. 2010;10:27.
Keywords:

HIV; pulmonary disease; chronic obstructive; COPD exacerbation; airflow limitation

Supplemental Digital Content

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.